<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641862</url>
  </required_header>
  <id_info>
    <org_study_id>HD052143</org_study_id>
    <nct_id>NCT00641862</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Vitamin B12 in Pregnant Indian Women</brief_title>
  <acronym>B12</acronym>
  <official_title>Randomized Trial of Vitamin B12 in Pregnant Indian Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. John's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind trial among 300 pregnant Indian women in order to
      determine the effectiveness of vitamin B12 supplementation in improving maternal B12 status.
      Secondary aims for this trial include maternal hemoglobin, maternal weight gain during
      pregnancy and infant birthweight. All women will receive standard of prenatal obstetric care,
      including routine supplementation with iron and folate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of poor fetal growth and adverse maternal and infant birth outcomes is quite
      high in India, and several lines of evidence suggest that maternal nutritional status may be
      an important factor. We have previously performed extensive evaluations of poor fetal and
      infant outcomes in other settings, and found that maternal micronutrient supplementation (B
      vitamins including vitamin B12, plus vitamins C and E) in HIV positive Tanzanian mothers
      decreased the risk of low birthweight (&lt;2500 g) by 44% (RR (95% CI) 0.56 (0.38-0.82)), severe
      preterm birth (&lt;34 weeks of gestation) by 39% (RR 0.61 (0.38-0.96)), and small size for
      gestational age at birth by 43% (RR 0.57 (0.39-0.82)). In a prospective cohort study of 410
      pregnant Indian women, we recently found a strong relationship between maternal serum vitamin
      B12 concentration and risk of infant intrauterine growth retardation (IUGR). Compared to
      women in the highest tertile of serum B12 concentration, women in the lowest tertile were
      significantly more likely to have IUGR infants, after controlling for maternal age, weight,
      education, and parity (OR (95% CI) 5.98 (1.72-20.74)). We now propose a randomized,
      double-blind trial among 300 pregnant Indian women in order to determine the effectiveness of
      vitamin B12 supplementation (50 µg daily) in improving maternal B12 status. Secondary aims
      for this exploratory trial include maternal hemoglobin, maternal weight gain during pregnancy
      and infant birthweight. All women will receive standard of prenatal obstetric care, including
      routine supplementation with iron and folate. The study will be a collaborative effort
      between the Division of Nutrition, St John's Research Institute, Bangalore, India, and the
      Department of Nutrition, Harvard School of Public Health, Boston, US.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Maternal Serum B12 Concentration From 1st to 3rd Trimester</measure>
    <time_frame>from 1st to 3rd trimester</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Maternal Hemoglobin Levels, Maternal Weight Gain and Infant Birth-weight.</measure>
    <time_frame>Maternal hemoglobin levels will be assessed at weeks 24 and 34 pre-pregnancy and at 6 weeks post-partum. Maternal weight gain will be assessed monthly until delivery and at 6 weeks post-partum. Infant birth-weight will be assessed at birth.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Childhood Neurodevelopment/Neurocognitive Function</measure>
    <time_frame>18 and 30 months</time_frame>
    <description>Neurodevelopmental status and neurocognitive function are measured by measured by the cognitive scale of the Bayley scales of infant development, 3rd edition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Vitamin B12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin B12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B12</intervention_name>
    <description>Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery</description>
    <arm_group_label>Vitamin B12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women at or before 14 weeks gestational age.

        Exclusion Criteria:

          -  Women who anticipate moving outside of the study area before study completion

          -  Those with twin or multiple pregnancies

          -  Those who test positive for hepatitis B (HepBSAg), HIV or Syphilis (VDRL)

          -  Those taking vitamin supplements in addition to folate and iron

          -  Those with a serious pre-existing medical condition, defined as conditions that
             require chronic or daily medical therapy such as connective tissue diseases,
             hypertension not related to pregnancy, inflammatory bowel disease, active
             tuberculosis, symptomatic heart disease, and insulin dependent diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher P Duggan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anura Kurpad, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. John's Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krishnamachari Srinivasan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. John's Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. John's Medical Research Institute, St. John's National Academy of Health Sciences</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560-034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Muthayya S, Dwarkanath P, Mhaskar M, Mhaskar R, Thomas A, Duggan C, Fawzi WW, Bhat S, Vaz M, Kurpad A. The relationship of neonatal serum vitamin B12 status with birth weight. Asia Pac J Clin Nutr. 2006;15(4):538-43.</citation>
    <PMID>17077072</PMID>
  </reference>
  <reference>
    <citation>Muthayya S, Kurpad AV, Duggan CP, Bosch RJ, Dwarkanath P, Mhaskar A, Mhaskar R, Thomas A, Vaz M, Bhat S, Fawzi WW. Low maternal vitamin B12 status is associated with intrauterine growth retardation in urban South Indians. Eur J Clin Nutr. 2006 Jun;60(6):791-801. Epub 2006 Jan 11.</citation>
    <PMID>16404414</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <results_first_submitted>August 22, 2016</results_first_submitted>
  <results_first_submitted_qc>August 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2016</results_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harvard School of Public Health</investigator_affiliation>
    <investigator_full_name>Christopher Duggan</investigator_full_name>
    <investigator_title>Professor in the Department of Nutrition</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Maternal Nutritional Status</keyword>
  <keyword>Vitamin B12</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin B12</title>
          <description>Vitamin B12
Vitamin B12: Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin B12</title>
          <description>Vitamin B12
Vitamin B12: Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="183"/>
            <count group_id="B3" value="366"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" lower_limit="20" upper_limit="24"/>
                    <measurement group_id="B2" value="22" lower_limit="20" upper_limit="24"/>
                    <measurement group_id="B3" value="22" lower_limit="20" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Maternal Serum B12 Concentration From 1st to 3rd Trimester</title>
        <time_frame>from 1st to 3rd trimester</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin B12</title>
            <description>Vitamin B12
Vitamin B12: Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Maternal Serum B12 Concentration From 1st to 3rd Trimester</title>
          <units>pmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="-54.8" upper_limit="83.5"/>
                    <measurement group_id="O2" value="-37.6" lower_limit="-66.5" upper_limit="-10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Maternal Hemoglobin Levels, Maternal Weight Gain and Infant Birth-weight.</title>
        <time_frame>Maternal hemoglobin levels will be assessed at weeks 24 and 34 pre-pregnancy and at 6 weeks post-partum. Maternal weight gain will be assessed monthly until delivery and at 6 weeks post-partum. Infant birth-weight will be assessed at birth.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Childhood Neurodevelopment/Neurocognitive Function</title>
        <description>Neurodevelopmental status and neurocognitive function are measured by measured by the cognitive scale of the Bayley scales of infant development, 3rd edition</description>
        <time_frame>18 and 30 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin B12</title>
          <description>Vitamin B12
Vitamin B12: Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christopher Duggan</name_or_title>
      <organization>Harvard T.H. Chan School of Public Health</organization>
      <phone>617-355-7612</phone>
      <email>christopher.duggan@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

